POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Though programmed cell death‐ligand 1 (PD‐L1) has been used in predicting the efficacy of immune checkpoint blockade (ICB), it is insufficient as a single biomarker. As a key effector of an intrinsically mutagenic microhomology‐mediated end joining (MMEJ) pathway, DNA polymerase theta (POLQ) was overexpressed in various malignancies, whose expression might have an influence on genomic stability, therefore altering the sensitivity to chemotherapy and immunotherapy.

• Publication year

  2024

• Venue

  Cancer Medicine

• Publication date

  2024-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.6962PMID 38457207PMCID 10922026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

  2024cited by this paper
• Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

  2022cited by this paper
• Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes

  2021cited by this paper
• Signatures of copy number alterations in human cancer

  2021cited by this paper
• Targeting the DNA damage response in immuno-oncology: developments and opportunities

  2021cited by this paper
• Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

  2021cited by this paper
• Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience

  2021cited by this paper
• Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis

  2021cited by this paper
• A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

  2021cited by this paper
• Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

  2021cited by this paper
• Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

  2020cited by this paper
• Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.

  2020cited by this paper
• SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients

  2020cited by this paper
• Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy

  2020cited by this paper
• Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer

  2020cited by this paper
• The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

  2019cited by this paper
• Determining cell-type abundance and expression from bulk tissues with digital cytometry

  2019cited by this paper
• Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer.

  2019cited by this paper
• Genetic determinants of cellular addiction to DNA polymerase theta

  2019cited by this paper
• The repertoire of mutational signatures in human cancer

  2018cited by this paper
• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

  2018cited by this paper
• Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

  2018cited by this paper
• Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

  2018cited by this paper
• Landmarks in the treatment of muscle-invasive bladder cancer

  2017cited by this paper
• Elements of cancer immunity and the cancer–immune set point

  2017cited by this paper
• IFN Signaling and ICB Resistance: Time is on Tumor's Side.

  2017cited by this paper
• IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade

  2017cited by this paper
• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

  2017cited by this paper
• Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

  2017cited by this paper
• First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

  2017cited by this paper
• Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma

  2017cited by this paper
• Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

  2017cited by this paper
• IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade

  2017cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

  2016cited by this paper
• Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

  2015cited by this paper
• DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity.

  2015cited by this paper
• Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Molecular subtyping of invasive bladder cancer: time to divide and rule?

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

  2014cited by this paper
• The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

  2012cited by this paper
• Tumor and Stem Cell Biology Cancer Research A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown

  2010cited by this paper
• DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability

  2010cited by this paper
• A ‘DNA replication’ signature of progression and negative outcome in colorectal cancer

  2010cited by this paper
• DNA polymerase θ is preferentially expressed in lymphoid tissues and upregulated in human cancers

  2004cited by this paper
• Rev. Latino-am. Enfermagem How to Cite This Article the Impact of the Use of Different Types of Gloves and Bare Hands for Preparation of Clean Surgical Instruments 1

  year unknowncited by this paper

• Pancancer analysis of DNA damage repair gene mutations and their impact on immune regulatory gene expression

  2025cites this paper
• Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair

  2025cites this paper
• Contributions of DNA double strand break repair pathways to DNA crosslink repair.

  2025cites this paper
• POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

  2024cites this paper
• POLQ immunostaining behaves as a prognostic factor for pancreatic carcinoma

  2024cites this paper